WOBURN, Mass., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company
developing oncolytic immunotherapies derived from its Immulytic™ platform, today announced that Robert Coffin, Ph.D., Chief
Executive Officer and Director of Replimune, will present at the Leerink Partners Roundtable Series: Rare Disease & Oncology on
Wednesday, October 3, 2018 at 11:30 AM ET at the Lotte New York Palace Hotel in New York, NY.
About Replimune
Replimune Group Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of “oncolytic
immunotherapies” for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the
direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released.
The Company’s Immulytic™ platform is designed to maximize systemic immune activation, in particular to tumor
neoantigens, through robust viral mediated immunogenic tumor cell killing and the delivery of optimal combinations of
immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune
checkpoint blockade and other approaches to cancer treatment. Replimune intends to progress these therapies rapidly through
clinical development in combination with other immuno-oncology products with complementary mechanisms of action. For more
information, please visit www.replimune.com.
Replimune Contact
Pamela Esposito, Ph.D.
Replimune Group Inc.
617.233.6988
pamela@replimune.com
Investor Inquiries
Chris Brinzey
Westwicke Partners
339.970.2843
chris.brinzey@westwicke.com
Media Inquiries
Arleen Goldenberg
Verge Scientific Communications
917.548.1582
agoldenberg@vergescientific.com
